Ziopharm Oncology (NASDAQ: ZIOP) reported Q2 EPS of ($1.01), $0.90 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $1.52 million.

For earnings history and earnings-related data on Ziopharm Oncology (ZIOP) click here.